Article

Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects

Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Alimentary Pharmacology & Therapeutics (Impact Factor: 4.55). 02/2008; 27(2):186-96. DOI: 10.1111/j.1365-2036.2007.03564.x
Source: PubMed

ABSTRACT Gastric emptying scintigraphy (GES) using a radio-labelled meal is used to measure gastric emptying. A nondigestible capsule, SmartPill, records luminal pH, temperature, and pressure during gastrointestinal transit providing a measure of gastric emptying time (GET).
To compare gastric emptying time and GES by assessing their correlation, and to compare GET and GES for discriminating healthy subjects from gastroparetics.
Eighty-seven healthy subjects and 61 gastroparetics enrolled with simultaneous SmartPill and GES. Fasted subjects were ingested capsule and [(99m)Tc]-SC radio-labelled meal. Images were obtained every 30 min for 6 h. Gastric emptying time and percentage of meal remaining at 2/4 h were determined for each subject. The sensitivity/specificity and receiver operating characteristic analysis of each measure were determined for each subject.
Correlation between GET and GES-4 h was 0.73 and GES-2 h was 0.63. The diagnostic accuracy from the receiver operating characteristic curve between gastroparetics and healthy subjects was GET = 0.83, GES-4 h = 0.82 and GES-2 h = 0.79. The 300-min cut-off time for GET gives sensitivity of 0.65 and specificity of 0.87 for diagnosis of gastroparesis. The corresponding sensitivity/specificity for 2 and 4 h standard GES measures were 0.34/0.93 and 0.44/0.93, respectively.
SmartPill GET correlates with GES and discriminates between healthy and gastroparetic subjects offering a nonradioactive, standardized, ambulatory alternative to scintigraphy.

Download full-text

Full-text

Available from: Jeff Lackner, Aug 28, 2015
1 Follower
 · 
95 Views
  • Source
    • "The best correlation was with the GES at 4 hours with a correlation coefficient of 0.73. The capsule detects more delay in GET than GES (65% vs. 44%) presumably because it also measures the fasting state.10 On the other hand, the cut-off for rapid GET with the capsule is unclear since the 2-hour proposed cut-off is not validated against scintigraphy and there is only one study which has shown that WMC was diagnostically useful but the sample size was small.5 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Assessment of transit through the gastrointestinal tract provides useful information regarding gut physiology and patho-physiology. Although several methods are available, each has distinct advantages and limitations. Recently, an ingestible wireless motility capsule (WMC), similar to capsule video endoscopy, has become available that offers a less-invasive, standardized, radiation-free and office-based test. The capsule has 3 sensors for measurement of pH, pressure and temperature, and collec-tively the information provided by these sensors is used to measure gastric emptying time, small bowel transit time, colonic transit time and whole gut transit time. Current approved indications for the test include the evaluation of gastric emptying in gastroparesis, colonic transit in constipation and evaluation of generalised dysmotility. Rare capsule retention and malfunc-tion are known limitations and some patients may experience difficulty with swallowing the capsule. The use of WMC has been validated for the assessment of gastrointestinal transit. The normal range for transit time includes the following: gastric empty-ing (2-5 hours), small bowel transit (2-6 hours), colonic transit (10-59 hours) and whole gut transit (10-73 hours). Besides avoiding the use of multiple endoscopic, radiologic and functional gastrointestinal tests, WMC can provide new diagnoses, leads to a change in management decision and help to direct further focused work-ups in patients with suspected disordered motility. In conclusion, WMC represents a significant advance in the assessment of segmental and whole gut transit and mo-tility, and could prove to be an indispensable diagnostic tool for gastrointestinal physicians worldwide.
    Journal of neurogastroenterology and motility 04/2014; 20(2):265-70. DOI:10.5056/jnm.2014.20.2.265 · 2.70 Impact Factor
  • Source
    • "Previous studies have shown a good correlation between gastric emptying of a radiolabeled meal and gastric residence time of the capsule [11]. Furthermore, significant differences in gastric emptying time of the capsule were observed between healthy controls and patients with a history of gastroparesis [12]. The wireless motility capsule also was capable of detecting differences in the frequency and motility index of antral and duodenal contractions in patients with severe gastroparesis compared to healthy controls or patients with mild to moderate gastroparesis [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A wireless motility capsule is a new method for ambulatory assessment of transit times and motility throughout the gastrointestinal tract. The objective of this study was to evaluate the ability of a wireless motility capsule to detect drug effects on gastric emptying time (GET) and gastric contractility. 15 healthy adults were administered in random order saline, erythromycin IV 150 mg, or morphine IV 0.05 mg/kg BW. Subjects ate a standard meal after each infusion, and subsequently ingested the motility capsule. Data were recorded for 8 hours, and the results were analyzed using the manufacturer's software. GET was significantly faster after erythromycin than either saline or morphine. Morphine tended to delay emptying of the capsule compared to saline. There was a trend toward a greater frequency of gastric contractions with erythromycin and a reduced frequency of gastric contractions with morphine that did not reach statistical significance. A wireless motility capsule successfully detected acceleration of gastric emptying induced by erythromycin, and retardation of gastric motility caused by morphine. These results indicate that a wireless motility capsule is a promising technique to assess pharmacologic effects on gastric transit and contractility and aid in development of drugs for gastric motor disorders.
    BMC Gastroenterology 01/2014; 14(1):2. DOI:10.1186/1471-230X-14-2 · 2.11 Impact Factor
  • Source
    • "Dyspepsia can be easily evaluated through a questionnaire about characteristic symptoms, although gastric emptying time is not so easily assessed. The tools available to estimate gastric emptying time are: technetium-99 m scintigraphy (gold –pattern) [9]; time of appearance of acetaminophen in blood after its ingestion [10]; imaging studies using 3D ultrasonography and nuclear resonance [11,12]; the smart pill (which seems to be a practical and promising method) [13]; and octanoic acid breath test using 13carbon (with 89% sensitivity compared to gold-standard technetium-99 m scintigraphy) [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dyspepsia is common among end-stage renal disease (ESRD) patients and its association with delayed gastric emptying is not well established. We assessed the association of dyspepsia with gastric emptying time in ESRD patients undergoing hemodialysis (HD). Dyspepsia was assessed through the Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ). PADYQ's scores >= 6 classified participants as dyspeptic. The octanoic acid breath test using 13carbon was employed to assess the gastric emptying time. Based on the test, time in minutes to metabolize the first half of the 13carbon in the test meal (t1/2) was calculated. Association of dyspepsia with gastric emptying time was tested by the correlation between PADYQ scores and t1/2, and also by comparing t1/2 between dyspeptics and non-dyspeptics. There were 34 (68.0%) dyspeptic patients. Dyspepsia score was positively correlated with t1/2 (r = 0.366; p = 0.009). Dyspeptics had longer t1/2 compared to non-dyspeptics, respectively, 238.0 +/- 92.9 versus 185.5 +/- 45.5 minutes (p = 0.042). Delayed gastric emptying was associated with dyspepsia. Prokinetic medications could have a role in preventing or relieving dyspeptic symptoms among HD patients. Future research in larger samples is necessary to confirm this association.
    BMC Nephrology 12/2013; 14(1):275. DOI:10.1186/1471-2369-14-275 · 1.52 Impact Factor
Show more